Aktienanalyse zu bioAffinity Technologies Inc (BIAF)BIAFbioAffinity Technologies Inc

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

bioAffinity Technologies Inc is not a good buy right now due to significant financial losses and declining revenues. The current price is $4.87, with a year-to-date change of -73.39%, indicating a severe downturn. Additionally, the company reported a Q1 EPS of -$0.81 and a 27% drop in revenue to $1.4 million, suggesting ongoing financial instability.